TABLE 1

Fold Change in Average Tumor Volume from Baseline of Combination Therapies vs. Corresponding Monotherapies and Bliss Synergy Interaction Values

	¹⁷⁷Lu-lilotomab (MBq/kg)	Fold change from day 0
Study day	¹⁷⁷Lu-lilotomab (MBq/kg)	Without rituximab	With rituximab	Interaction value
3	0	2.2	2.2
	150	1.7	1.6	0.99 (0.41, 2.37)
	350	2.3	1.7	0.77 (0.32, 1.84)
7	0	6.1	5.5
	150	3.3	2.4	0.80 (0.33, 1.91)
	350	2.7	1.6	0.66 (0.28, 1.57)
9	0	9.2	8.9
	150	4.4	3.0	0.70 (0.29, 1.68)
	350	3.1	1.6^†	0.53 (0.22, 1.23)
10	0	11.8	10.6
	150	4.3	3.1	0.79 (0.33, 1.89)
	350	3.2	1.7	0.61 (0.26, 1.46)
13	0	20.4	16.6
	150	5.0	3.2	0.79 (0.33, 1.89)
	350	3.1	1.3^†	0.51 (0.22, 1.23)
15	0	36.2	28.8
	150	5.7	3.3	0.74 (0.31, 1.77)
	350	3.3	1.3^†	0.50 (0.21, 1.21)
17	0	57.8	42.6
	150	7.7	3.5^*	0.61 (0.25, 1.47)
	350	3.5	1.0^†	0.39 (0.16, 0.94)^‡
20	0	116.6	80.2
	150	10.2	4.2^*	0.60 (0.25, 1.43)
	350	4.1	1.0^†	0.36 (0.15, 0.86)^‡

↵* Significant rituximab effect with 150 MBq/kg ¹⁷⁷Lu-lilotomab (P < 0.05).
↵† Significant rituximab effect with 350 MBq/kg ¹⁷⁷Lu-lilotomab (P < 0.05).
↵‡ Significant synergism (P < 0.05).
Data in parentheses are 90% confidence intervals.